GE HealthCare carries broad sell-side coverage. Reviewing 10 recent, individually verified price targets produced an arithmetic mean of about $88.90, which rounds to a central target of $89. This is close to, though not identical to, the independently reported S&P Global average of roughly $88.25 across 22 analysts. The target range is unusually wide: the low sits at $79 (Citi's Joanne Wuensch, Neutral) and the high at $110 (Argus Research's David Toung, Buy).
Views cluster in three groups. Neutral-rated analysts such as UBS, JPMorgan, and BofA hold targets of $80 to $84, reflecting caution on near-term earnings growth and margin pacing. A broad middle of Outperform/Buy ratings—including RBC Capital, Mizuho, Stifel, and BTIG—carries targets of $90 to $91. The most bullish, Barclays at $95 and Argus at $110, emphasize below-peer valuation and management's improved guidance. The dispersion shows analysts agree on direction but not on how much valuation expansion is justified. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
GE HealthCare Technologies (GEHC) closed near $80.84 in the latest session, giving the stock a market capitalization of roughly $36 billion and a trailing P/E around 17. Reaching the $89 central target requires a gain of about 10%, a modest move that still means clearing the stock's 52-week high of approximately $89.77.
The path is plausible but not automatic. The company's third-quarter report exceeded expectations, and management raised its outlook and increased the dividend, signaling confidence. Argus Research has argued shares trade near 15 times 2027 adjusted EPS, below the roughly 18 times average for its MedTech coverage. Closing that gap, combined with sustained mid-single-digit organic growth and margin expansion, is the core mechanism by which the stock could approach $89.
The most important structural level is the 52-week high near $89.77, which essentially overlaps with the $89 central target. This makes $89–$90 a meaningful resistance zone rather than a purely symbolic number; a decisive close above it would break the stock out of its long-term range. On the downside, the round-number $80 level has served as a consolidation area, while the 52-week low near $58.75, set earlier in 2026, marks the broader floor. The stock's 52-week range of roughly $59 to $90 underscores how volatile the path has been even as the business has improved.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms vary in methodology. Investors tracking the $89 target should watch the next quarterly earnings report, guidance revisions, and any changes to analyst estimates. China policy developments, hospital capital-expenditure data, and MedTech peer results also matter, as they influence both the demand outlook and the valuation multiple. Margin trajectory and order conversion rates will be the clearest signposts for whether the re-rating argument holds. From what I see, monitoring these elements closely helps frame the probability of hitting the target.
The $89 central target, derived from the arithmetic mean of 10 verified analyst price targets, is attainable but not a foregone conclusion. It requires only a modest gain of about 10%, yet it coincides with the stock's 52-week high, meaning the shares must break through established resistance rather than merely drift higher. Support comes from improving fundamentals, a below-peer valuation, and management's raised guidance; the principal obstacles are China-related uncertainty, pricing pressure, and execution on margins. The wide $79-to-$110 target range shows analysts themselves are divided. Whether GE HealthCare Technologies (GEHC) reaches $89 will likely hinge on continued margin delivery and whether the market is willing to re-rate the stock toward the MedTech peer multiple.
In my analysis of names like GEHC, I often turn to AI Daily Buy/Sell Signals for an additional layer of insight. This tool applies artificial intelligence to scan thousands of stocks and generate adaptive Buy, Sell, or Hold signals based on technical behavior and shifting market conditions. It serves as a practical complement to fundamental work when evaluating opportunities in the MedTech sector or elsewhere.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The 10-day RSI Indicator for GEHC moved out of overbought territory on November 11, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In 21 of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at 66%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GEHC as a result. In 44 of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.
The Moving Average Convergence Divergence Histogram (MACD) for GEHC turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 20 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GEHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 60%.
GEHC broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
GEHC moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GEHC crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
The 50-day moving average for GEHC moved above the 200-day moving average on November 11, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +7.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where GEHC advanced for three days, in 155 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
The Aroon Indicator entered an Uptrend today. In 109 of 169 cases where GEHC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. GEHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.390) is normal, around the industry mean (4.142). P/E Ratio (18.938) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.666) is also within normal values, averaging (11.253). Dividend Yield (0.002) settles around the average of (0.011) among similar stocks. P/S Ratio (1.363) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GEHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices